Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults-Reference-Cited by-同舟云学术

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

Published:2020-11-11 Issue:5 Volume:17 Page:1366-1373
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Leroux-Roels Isabel¹,Leroux-Roels Geert¹^ORCID,Shukarev Georgi²,Schuitemaker Hanneke³^ORCID,Cahill Conor⁴^ORCID,de Rooij Richard⁴^ORCID,Struijs Martin³,van Zeeburg Hester⁵,Jacquet Jeanne-Marie³^ORCID

Affiliation:

1. Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium

2. Janssen Vaccines AG, Bern, Switzerland

3. Janssen Vaccines & Prevention B.V., Leiden, The Netherlands

4. Takeda Pharmaceuticals, Zurich, Switzerland

5. DCPrime BV, Leiden the Netherlands

Funder

Bill and Melinda Gates Foundation

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1812315

Reference38 articles.

1. Poliomyelitis: A Review

2. WHA 41st World Health Assembly. Global eradication of poliomyelitis by 2000. Geneva World Health Organization [resolution WHA41.28]. 1988 [accessed 2020 Mar 16]. http://polioeradication.org/wp-content/uploads/2016/07/19880513_resolution-2.pdf.

3. Progress Toward Polio Eradication — Worldwide, January 2016–March 2018

4. The polio endgame: securing a world free of all polioviruses

5. World Health organization. Global polio eradication initiative. Polio this week. 2020 [accessed 2020 Mar 16]. http://polioeradication.org/polio-today/polio-now/this-week/.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 30-Year Development of Inactivated Virus Vaccine in China;Pharmaceutics;2023-12-02

2. Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study;Vaccine;2023-03

3. Poliovirus Vaccine—Inactivated;Plotkin's Vaccines;2023

4. Promising opportunities to improve polio vaccines;Biological Products. Prevention, Diagnosis, Treatment;2022-07-02

5. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age;Human Vaccines & Immunotherapeutics;2022-03-28